- Home
- KROS vs MCS Comparison
KROS vs MCS Comparison
Compare KROS & MCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | MCS |
|---|---|---|
| Founded | 2015 | 1935 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 479.7M |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | KROS | MCS |
|---|---|---|
| Price | $10.93 | $15.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $22.25 | ★ $23.75 |
| AVG Volume (30 Days) | ★ 376.7K | 129.8K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | ★ 2.01% |
| EPS Growth | ★ 146.00 | N/A |
| EPS | ★ 2.30 | 0.77 |
| Revenue | $243,864,000.00 | ★ $758,458,000.00 |
| Revenue This Year | N/A | $11.78 |
| Revenue Next Year | N/A | $3.09 |
| P/E Ratio | ★ $4.78 | $20.69 |
| Revenue Growth | N/A | ★ 3.11 |
| 52 Week Low | $9.12 | $12.85 |
| 52 Week High | $22.55 | $18.80 |
Technical Indicators
Market Signals| Indicator | KROS | MCS |
|---|---|---|
| Relative Strength Index (RSI) | 17.12 | 40.59 |
| Support Level | N/A | $14.66 |
| Resistance Level | $15.21 | $15.98 |
| Average True Range (ATR) | 0.71 | 0.64 |
| MACD | -0.22 | -0.15 |
| Stochastic Oscillator | 7.37 | 10.16 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.